This is to our knowledge the first study of breast cancer revealing cellular heterogeneity with regard to HER2 expression, HER2 copy number, and ER expression through analysis of a substantial number of cells from neoadjuvant‐treated HER2+ breast cancer patients. The gene discussed is ERBB2; the disease is breast carcinoma.